Table 1.
Patients characteristics, CML stage and IM response. F: Female, M: Male, Δsis: Diagnosis, CP: chronic phase, BC: blastic crisis, AP: accelerated phase, IM: imatinib, Mol: molecular, Hem: hematologic, Cyt: cytogenetic, Hep: hepatic, MMR: major molecular reponse, NR: no reponse.
| Case number | Sex | Age (years) | Δsis | 1st line therapy | Type of relapse at IM therapy | IM dose (mg/d) | Maximum IM reponse | Time to acheive MMR (month) | Toxicity | Current RT-PCR status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 28 | CML (CP) | IM | Mol | 400 | MMR | 3.7 | No | Negative |
| 2 | F | 44 | CML (CP) | IM | Cyt | 400 | MMR | 9.2 | No | Positive |
| 3 | M | 50 | CML (CP) | 3X | Hem | 400 | MMR | 3 | No | Negative |
| 4 | F | 47 | CML (CP) | 1X | Hem | 400 | MMR | 6 | Hem | Positive |
| 5 | M | 55 | CML (BC) | IM | Hem | 600 | NR | — | Hem | — |
| 6 | F | 48 | CML (CP) | IM | Mol | 400 | MMR | 2 | Hep | Positive |
| 7 | F | 45 | CML (AP) | IM | Hem | 600 | MMR | 9.5 | Hem | Positive |